Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of NPX372, a Bispecific Antibody Targeting B7-H7 and CD3, in Selected Solid Tumor Malignancies

NCT07563829 is registered in ClinicalTrials.gov with NextPoint Therapeutics, Inc. as lead sponsor.

NCT NCT07563829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07563829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of NPX372, a Bispecific Antibody Targeting B7-H7 and CD3, in Selected Solid Tumor Malignancies
Lead sponsor
NextPoint Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 1, 2026
Completion date
July 1, 2027
Enrollment
81 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm